Skip to main content
Advanced Pharmaceutical Bulletin logoLink to Advanced Pharmaceutical Bulletin
. 2018 Mar 18;8(1):29–38. doi: 10.15171/apb.2018.004

Construction and Development of a Cardiac Tissue-Specific and Hypoxia-Inducible Expression Vector

Shahrooz Ghaderi 1,2,3,#, Neda Alidadiani 1,#, Jafar Soleimani Rad 4, Hamid Reza Heidari 5, Nafi Dilaver 6, Behzad Mansoori 1, Reza Rhabarghazi 7,8, Rezayat Parvizi 9, Vahid Khaze Shahgoli 1, Behzad Baradaran 1,*
PMCID: PMC5896393  PMID: 29670836

Abstract

Purpose: Cardiovascular gene therapy is a sophisticated approach, thanks to the safety of vectors, stable transgene expression, delivery method, and different layers of the heart. To date, numerous expression vectors have been introduced in biotechnology and biopharmacy industries in relation to genetic manipulation. Despite the rapid growth of these modalities, they must be intelligently designed, addressing the cardiac-specific transgene expression and less side effects. Herein, we conducted a pilot project aiming to design a cardiac-specific hypoxia-inducible expression cassette.

Methods: We explored a new approach to design an expression cassette containing cardiac specific enhancer, hypoxia response elements (HRE), cardiac specific promoter, internal ribosome entry site (IRES), and beta globin poly A sequence to elicit specific and inducible expression of the gene of interest. Enhanced green fluorescent protein (eGFP) was sub-cloned by BglII and NotI into the cassette. The specificity and inducible expression of the cassette was determined in both mouse myoblast C2C12 and mammary glandular tumor 4T1 as ‘twin’ cells. eGFP expression was evaluated by immunofluorescence microscope and flow cytometry at 520 nm emission peak.

Results: Our data revealed that the designed expression cassette provided tissue specific and hypoxia inducible (O2<1%) transgene expression.

Conclusion: It is suggested that cardiac-specific enhancer combined with cardiac-specific promoter are efficient for myoblast specific gene expression. As well, this is for the first time that HRE are derived from three well known hypoxia-regulated promoters. Therefore, there is no longer need to overlap PCR process for one repeated sequence just in one promoter.

Keywords: Hypoxia, Hypoxia response element, Cis regulatory elements

Introduction

Since identification and description of hypoxia-inducible factor 1 (HIF-1) by Wang et al.,1 more than 200,000 articles have been published in scientific literatures. HIF-1 is an inducible transcription factor, which binds to hypoxia response elements (HREs) or enhancer elements during hypoxia. HREs are located in the upstream of promoter region. HIF-1 regulates several genes, such as vascular endothelial growth factor (VEGF) and erythropoietin (EPO).2 hypoxia inducible factor-1 alpha (HlF-1) is comprised of a heterodimer basic helix-loop-helix (bHLH) transcriptional complex and is divided into distinct subsets, including HIF-1α and aryl hydrocarbon receptor nuclear translocator (ARNT), encoding a protein that is referred to beta (β) subunit. HIF-1 belongs to a conserved subfamily of PER-ARNT-SIM (PAS), which functions as oxygen sensors. The PAS domain is a subfamily of bHLH, which is a transcription factor. The HIF family consists of HIF-1α, -1β, -2α, -2β, -3α, -3β.3,4 In normoxia, HIF-1α is degraded by ubiquitin-mediated proteolysis activity, while being transcribed into mature RNA under hypoxic conditions, leading to an increase in oxygen delivery to the tissues. Therefore, HIF-1α has an essential role both in physiologic and pathologic conditions, including, but not limited to, myocardial ischemia, coronary artery disease, organ rejection and some cancers.5,6

Among all the above-mentioned circumstances, HIF-1α plays a great role in cardiovascular diseases. Lack of oxygen contributes to augmented hypoxia in coronary and cardiac tissue, subsequently leading to a cardiac stroke. Despite the emergence of novel surgical and medical approaches, cardiac infarction is set to become the leading cause of death up to the year 2020.7 Several reports have indicated that cardiac function, if not completely, then partially, can be ameliorated following gene or cell therapy in experimental models of infarction.8,9 However, ectopic gene expression has its disadvantages, such as hemangioma or uncontrolled vascular formation. It is, therefore, essential to regulate gene expression via the modulation of upstream elements of promoters like HREs. It should also be noted that hypoxia may subsequently exist in other tissues as a result of physiologic statement. Hence, tissue specific gene expression is essential to develop suitable vectors for gene therapy. This approach is also considered to be useful for sophisticated studies in the field of biomedical research such as cellular imaging and tracking,10 genome editing,11 stem cell engineering,12 and the study of signaling pathways.13-15

In this study, we investigated the cardiac specific promoter and cardiac specific enhancer combined with HREs consensus sequence.

Materials and Methods

Expression cassette designing and cloning

In order to construct the expression cassette, all the elements were synthesized by Generay Biotechnology Company (Shanghai, China) and sub-cloned into pGH cloning vector by NdeI and NheI restriction enzymes (Fermentas, Germany) (Figure 1). eGFP was sub-cloned into the cassette by Bglll and Notl (Figure 2). Briefly, 1 µg plasmid DNA was digested by BglII and NotI (Fermentas, Germany) and the relevant buffer was added up to the final volume of 20 µl in 37 °C for 1 h. Enzymatic reaction was inactivated by chloroform and the cloning procedure was confirmed by HindIII digestion.

Figure 1.

Figure 1

Schematic view of expression cassette. Expression cassette contains CASQ2 enhancer, HRE, MLC2v promoter, IRES, and β-globin poly A sequence.

Figure 2.

Figure 2

 Schematic view of eGFP cloning into the cassette. eGFP was cloned into the cassette by NotI and BglII restriction enzymes.

Bacterial strains and plasmid preparation

Two strains of Escherichia Coli (E. coli) were used including DH5α and DH10β (Top10, Invitrogen, Thermo Fisher Scientific, USA). The plasmid was transformed into cells using the calcium chloride (CaCl2) method.16 E. coli bearing the desired plasmid was cultured in lysogeny broth (LB) media for 16 hrs at 37 °C in a shaker incubator. Cells with a density of 3-4×109 cells/ml with OD600=3 were harvested and DNA was extracted by plasmid DNA extraction kit (Qiagen, Midiprep Plasmid DNA Extraction Kit).

Cell Culture

The mouse myoblast cell line C2C12 (CRL-1772) and the mouse mammary gland cell line 4T1 (CRL-2539) was purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). C2C12 cells were cultured in high glucose Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS, Invitrogen, USA) and 0.584 g/L L-glutamine (Sigma-Aldrich, USA) in 37°C incubator and humidified 5% CO2 and 95% air.17 4T1 cells, a 6-thioguanine resistant cell line,18 were cultured in RPMI-1640 (Sigma-Aldrich, USA) and 10% FBS (Invitrogen Gibco) in 37°C incubator and humidified atmosphere with 5% CO2 and 95% air. Cell lines were passaged after 80% confluence.

The induction of hypoxic condition

To create hypoxia, C2C12 and 4T1 cell lines were incubated for 90 min in a hypoxic condition, containing 94% N2, 4% CO2 and 1% O2, and hanks buffer. As a normoxia control “twin” cells were kept in a normoxic incubator.

Plasmid Transient Transfection

For achieving transient transfection, Gene Pulser XcellTM electroporation system (Bio-Rad, USA) was used. Following 60% confluence, media was removed and cells were harvested using 0.25% Trypsin-EDTA solution. Approximately 4-5 ×106 cells were harvested by adding 3 ml complete media and then centrifuged for 5 min at 1000g and 4°C.19 Thereafter, cells were re-suspended in 400µl opti-MEM (buffer O).20 Then, 10µg of supercoiled DNA was overlaid to the cell suspension and mixed in wells. The cuvette was placed on ice for 5 min. Then, cells were transfected with the optimized exponential protocol (one shock for 18 seconds, at a voltage 120).

Fluorescence microscopy

Slides were visualized with a Zeiss Axioplan using 485 band pass filters set to view eGFP. All images were analyzed with AxioCam digital camera and Zeiss proprietary software (Axiovision Ver. 3.0.6.0). Images were manipulated in Adobe Photoshop 5.5.

Flow cytometry

eGFP expression was detected 48 hrs after transfection. Myocyte cells were harvested by trypsin/EDTA. Cells were centrifuged at 1000g for 10 min at 4°C. The cells were then washed three times with 500 µl of PBS. Fluorescence-activated cell sorting (FACS) caliber-micro flow cytometer (Becton Dickinson, NJ, USA) was used to analyze eGFP expression. GFP was excited by an argon laser and fluorescence’s at 485/520 nm band pass filter in the FL1 channel. All raw data were analyzed using FlowJo software version 7.6.1.

Western Blotting

Cells in the both hypoxia and normoxia groups were collected from the wells and their protein contents were detected using an extraction Kit (Santa Cruz, USA) following the manufacturer’s protocol. Total protein concentration was measured using a Nanodrop (Thermo-Scientific, USA). Samples were prepared for western blotting by adding loading buffer to each sample. Proteins were electrophoresed on 12% SDS-polyacrylamide gel and transferred to PVDF membranes. The membranes were blocked by incubating with 0.3 g bovine serum albumin in 10 ml of washing buffer at 4ºC overnight. Membranes were then washed three times with PBS for 10 min. Then, the membranes were incubated with anti-HIF-1α antibody (dilution: 1:500; Santa-Cruz) for 4 hrs at 4ºC. The membranes were then washed three times for 10 min each and incubated with the secondary antibody for 2 hrs. Roche ECL kit and semi-dry X-ray were used for imaging of immunoreactive protein bands.

Results

eGFP Cloning confirmation with HindIII digestion

To confirm eGFP cloning, the expression cassette was digested by HindIII and positive colony was determined by three sharp plasmid DNA band, including 3000, 2000 and 1500 bps on gel electrophoresis. Meanwhile, empty expression cassette was digested into two bands on 2500 and 1500 bps (Figure 3A and B).

Figure 3.

Figure 3

A; Confirmation of eGFP cloning into the cassette. Expression cassette was linearized by HindIII two sharp plasmid DNA band on 2500 and 1500 bps (Ladder 4000bps). B; Confirmation of eGFP cloning into the cassette by HindIII digestion three sharp plasmid DNA band on 3000, 2000 and 1500bps (Ladder 3000bps).

Exploration of the CASQ2 enhancer and cardiac tissue specific promoter

Calsequestrin 2 (CASQ2) as a cardiac specific enhancer plus myosin light chain-2 (MLC2v) cardiac specific promoter provided tissue specificity. Thanks to highly cardiac specific sequence expression, eGFP was detected in myoblast C2C12 cell line, but not in 4T1 ‘twin’ cell.

Exploring of HRE

In this study, 35 putative sites, including 9 ARNT, HIF-1, and 26 sp1 from EPO, VEGF-A, and phosphoglycerate kinase 1 (PGK-1) promoters were driven (Figure 4A and B, Table 1). HRE sequence was analyzed for insulator boundary elements to prevent enhancer and promoter interaction (Table 2). The elements provided hypoxia inducible expression. eGFP was detected under hypoxia and was not expressed under normoxia condition.

Figure 4.

Figure 4

A; ARNT consensus sequence has been repeated 9 times in HRE. B; sp1 consensus sequence has been repeated 26 times in HRE

Table 1. 35 Putative sites that is existing on Hypoxia Responses Elements (HRE) including 9 ARNT and 26 sp1.

The JASPAR database
35 putative sites were predicted with these settings (80%) in sequence named 1
Model ID Model name Score Relative score Start End Strand predicted site sequence
MA0079.2 SP1 6.736 0.800936630165687 27 36 1 CCCCGGCGAC
MA0079.3 SP1 1.668 0.802126030842755 38 48 1 CTTCCTGCTCC
MA0079.3 SP1 14.558 0.964296987823859 44 54 1 GCTCCGCCCCT
MA0079.2 SP1 9.501 0.870571327605649 45 54 1 CTCCGCCCCT
MA0079.1 SP1 6.122 0.800408014237765 46 55 ­1 TAGGGGCGGA
MA0259.1 ARNT::HIF1A 8.788 0.928072894030867 81 88 1 CGGCGTGC
MA0259.1 ARNT::HIF1A 9.817 0.958770479367351 90 97 1 GGACGTGA
MA0259.1 ARNT::HIF1A 10.396 0.976043464702457 110 117 ­1 AGACGTGC
MA0259.1 ARNT::HIF1A 9.025 0.935143183364926 145 152 1 ATACGTGG
MA0259.1 ARNT::HIF1A 10.321 0.973806031368894 174 181 1 CTACGTGC
MA0079.1 SP1 7.476 0.847637728498468 188 197 ­1 CAGGCTGTGT
MA0079.2 SP1 6.736 0.800936630165687 212 221 1 CCCCGGCGAC
MA0079.3 SP1 1.668 0.802126030842755 223 233 1 CTTCCTGCTCC
MA0079.3 SP1 14.558 0.964296987823859 229 239 1 GCTCCGCCCCT
MA0079.2 SP1 9.501 0.870571327605649 230 239 1 CTCCGCCCCT
MA0079.1 SP1 6.122 0.800408014237765 231 240 ­1 TAGGGGCGGA
MA0259.1 ARNT::HIF1A 6.391 0.856564524690194 266 273 1 GAGCGTGT
MA0259.1 ARNT::HIF1A 4.936 0.813158318019073 281 288 ­1 CTACGGGC
MA0259.1 ARNT::HIF1A 8.854 0.930041835364402 306 313 ­1 AAACGTGC
MA0259.1 ARNT::HIF1A 8.575 0.921718583363548 316 323 1 CCGCGTGC
MA0079.1 SP1 6.765 0.822836896268513 344 353 1 CAGGGGCGGT
MA0079.2 SP1 7.611 0.822972926823903 345 354 ­1 CACCGCCCCT
MA0079.3 SP1 10.560 0.913997570755554 345 355 ­1 GCACCGCCCCT
MA0079.1 SP1 7.289 0.841114865450646 346 355 1 GGGGCGGTGC
MA0079.3 SP1 3.163 0.820934842377801 350 360 ­1 CTCCCGCACCG
MA0079.2 SP1 13.214 0.964080778453597 357 366 ­1 CCCCGCCTCC
MA0079.3 SP1 13.420 0.949979644996513 357 367 ­1 ACCCCGCCTCC
MA0079.1 SP1 11.046 0.972165113956893 358 367 1 GAGGCGGGGT
MA0079.3 SP1 3.129 0.820507083453258 362 372 ­1 CCCACACCCCG
MA0079.2 SP1 8.685 0.850020906950673 364 373 ­1 CCCCACACCC
MA0079.3 SP1 7.096 0.870416485031539 364 374 ­1 GCCCCACACCC
MA0079.2 SP1 7.202 0.812672532157377 368 377 ­1 CCCGCCCCAC
MA0079.2 SP1 8.757 0.851834179361406 369 378 ­1 TCCCGCCCCA
MA0079.3 SP1 10.509 0.913355932368739 369 379 ­1 ATCCCGCCCCA
MA0079.1 SP1 9.870 0.931144328158824 370 379 1 GGGGCGGGAT

Table 2. Insulator sequences have been located on HRE sequence.

Motif
PWM
Motif Sequence Input
Sequence
Name
Motif
Start
Location
Motif
Length
Motif
Orientation
Score
REN_20 CCTACGGGCACAGGGGACAC 1 87 20 + -12.4488
MIT_LM2 GCGTCGCCGGGGGGCCCAC 1 153 19 + -13.4637
MIT_LM2 GCGTCGCCGGGGGGCCCAC 1 338 19 + -13.4637
MIT_LM7 GAGACAGCACGTAGGGCAAG 1 189 20 + -7.41144
MIT_LM23 GAGACAGCACGTAGGGCAAG 1 189 20 + -5.62159

Hypoxia induction in C2C12 and 4T1 cell lines

HIF-1α at transcriptional and translational levels was stabilized under hypoxic condition. Then, we detected HIF-1α protein in hypoxic condition. Notably, we could not detect any HIF-1α protein in normoxia (Figure 5C).

Figure 5.

Figure 5

A; The results of immunofluorescence microscopy 48 hrs post transfection presented the specific expression of eGFP in the hypoxic condition at C2C12 myoblast cell line. eGFP was not detected in 4T1 cells in both hypoxic and normoxic condition. B; Flow cytometry results indicate the expression of eGFP under hypoxic condition in C2C12 cell line. C; Confirmation of hypoxia induction in both C2C12 and 4T1 cell lines by western blotting.

Expression cassette optimization

After subsequent transfection (48 h and 72 h), HREs exhibited the most intense fluorescence 48 hrs after transient transfection only in the hypoxic condition. Both cell lines were incubated under normoxic and hypoxic conditions to determine the function of HREs, including HIF-1α and sp1 transcription factor binding site. The expression vector generated a sharp eGFP expression, which was detected by immunofluorescence microscope 48 hrs after transfection in the C2C12 cell line under hypoxic conditions. On the other hand, No significant eGFP was detected in 4T1 cells. eGFP was expressed in C2C12 cell line but not 4T1 under hypoxic (O2<1%) condition. Moreover, we cannot detect any significant eGFP signals in C2C12 under normoxia. Flow cytometry results showed that myoblast cells expressed eGFP in hypoxia. However, eGFP was not express in 4T1 cells in both hypoxia and normoxia. Overall, experiments demonstrated that our designed cassette was expressed and, hence, functioned appropriately (Figure 5A and B).

eGFP measured 72h after transient transfection

After confirmation of hypoxia inducible and tissue specific expressions in expression cassette, the green fluorescence signals were analyzed 72 h and 96 h after transient transfection. eGFP signals were detected after 72h of transient transfection by the immune fluorescence microscopy at 520 band pass filter. However, we could not detect eGFP signals after 96 h after transfection (Figure 6).

Figure 6.

Figure 6

eGFP measurement 72 h after transfection. Arrow indicated the eGFP expression in C2C12.

Discussion

The results obtained through the experiments support some of our hypotheses. The current study explored the application of bioinformatics to improve the efficiency of cardiac gene therapy. Based on in silico analysis, we chose a cardiac specific cis-regulatory conserved motif that belonged to calsequestrin 2 (CASQ2) gene. The corresponding gene is specifically expressed in the heart. Tissue-specific cis-regulatory elements and correlated transcription factors, including myogenic regulatory factors (MRFs) like myogenic differentiation 1 (MYOD1), myogenic factor 5 (MYF5), myogenin and myogenin regulator factor 4 (MRF4), myogenic factor 6 (MYF6) interact with other transcription factors, particularly T box protein 2 (TBX2) and NK2 homeobox 5 (Nkx2.5).,21-24 which play a pivotal role in the correct differentiation and progressive formation of cardiac muscle (Table 3). This summary helps us to understand the role of specific cis-regulatory elements in designing tissue-specific expression cassettes. Both CASQ2 and MLC2v have a specific transcription factor binding site (TFBSs), which is efficient for cardiac-specific transgene expression.

Table 3. Cardiac specific transcription binding sites located on the CASQ2 enhancer.

Model ID Model name Score Relative score Start End Strand Predicted site sequence
MA0037.2 GATA3 3.279 0.820594050245556 7 14 1 AGAAAAAC
MA0052.2 MEF2A 5.498 0.801872773397612 51 65 1 TACCTTACATAGCTC
MA0052.2 MEF2A 8.618 0.843873743315264 90 104 -1 TCCTAAAAATGGAGT
MA0083.2 SRF 8.230 0.817813133982383 90 107 -1 GCATCCTAAAAATGGAGT
MA0499.1 Myod1 5.403 0.859668968902211 105 117 1 TGCAGTTGTTTCA
MA0052.2 MEF2A 17.095 0.957989840107549 118 132 1 GGCTAAAAATAAATC
MA0063.1 Nkx2-5 5.189 0.833795488710155 136 142 -1 TTCATTG
MA0035.3 Gata1 2.402 0.800738582375976 151 161 -1 GTCGTATCTAA
MA0037.2 GATA3 6.588 0.872659931082488 153 160 1 AGATACGA
MA0482.1 Gata4 2.124 0.802327146192479 176 186 -1 CTGTATCAGCG
MA0499.1 Myod1 0.838 0.800984257597511 191 203 -1 TTCACCAGTCGGA
MA0482.1 Gata4 2.114 0.802183373083414 202 212 -1 TCTTCCCTCTT
MA0482.1 Gata4 6.727 0.868505908295031 223 233 -1 TCTTGTCTTTT
MA0036.2 GATA2 7.206 0.849841616420247 224 237 -1 ACATTCTTGTCTTT
MA0035.3 Gata1 6.525 0.857230665045272 224 234 -1 TTCTTGTCTTT
MA0037.2 GATA3 6.588 0.872659931082488 226 233 1
MA0482.1 Gata4 6.776 0.869210396529448 244 254 -1 CCTTATTTCAT
MA0036.2 GATA2 5.069 0.820706175169384 245 258 -1 GCCTCCTTATTTCA
MA0035.3 Gata1 5.099 0.837692049986718 245 255 -1 TCCTTATTTCA
MA0037.2 GATA3 5.281 0.852094773556387 247 254 1 AAATAAGG
MA0482.1 Gata4 5.484 0.850634910838269 271 281 -1 CTTTCTCTTCT
MA0035.3 Gata1 2.802 0.806219259811756 272 282 -1 TCTTTCTCTTC
MA0037.2 GATA3 3.921 0.830695680797781 274 281 1 AGAGAAAG

Rincon et al.,25 previously showed that CASQ2 had a strong specificity for cardiac muscle. They made a construct consisting of CASQ2 and myosin heavy chain α (MHCα) as a cardiac specific promoter. In this study, we used MLC2v because of its cardiac-specific regulatory elements (Table 4). For inducible expression under hypoxic conditions, we used HREs derived from phosphoglycerate kinase (PGK1), VEGF-165, and EPO promoter. However, it was shown that HRE was a conserved sequence itself, but the most noted HRE sequence was derived from the EPO promoter.26 To make copies of inducible elements obtained from one promoter, overlap PCR must be performed. For easier construct production of the desired elements, we used promoter and 5ʹUTRs of three different genes.27,28

Table 4. Specific transcription factor and their binding sites are Myosin Light Chain 2 (MLC2).

Entrez_ID Symbol Alias GO_P GO_C
4250 SCGB2A2 MGB1 UGB2 na na
94234 FOXQ1 HFH1 transcription; regulation of transcription, DNA dependent;
hair follicle morphogenesis
nucleus
6927 TCF1 HNF1 HNF1A
LFB1 MODY3
Bone resorption; positive regulation of transcription from RNA polymerase II promoter nucleus;
transcription
factor complex
6722 SRF MCM1 Heart looping; transcription; signal transduction; multicellular organismal development; Heart development; positive regulation of transcription from RNA polymerase II promoter; muscle maintenance nucleus
3170 FOXA2 HNF3B
MGC19807
TCF3B
transcription; regulation of transcription, DNA dependent;
lung development; epithelial cell differentiation; positive regulation of transcription from RNA polymerase II promoter; branching morphogenesis of a tube
nucleus
3169 FOXA1 HNF3A
MGC33105
TCF3A
transcription; regulation of transcription, DNA dependent;
lung development; epithelial cell differentiation; hormone metabolic process; glucose homeostasis; positive regulation of transcription from RNA polymerase II promoter; branching morphogenesis of a tube
nucleus
4763 NF1 DKFZp686J1293
NFNS VRNF
WSS
cell cycle; Ras protein signal transduction; negative regulation of cell proliferation; regulation of glial cell differentiation; negative regulation of progression through cell cycle; regulation of small GTPase mediated signal
transduction
intracellular;
cytoplasm

HIF-1α belongs to a family of transcription factor with dimeric helices, containing basic amino acid residues that simplify DNA binding. bHLH proteins usually bind to a consensus sequence, well-known as HREs. Additionally, Sp1 is a zinc finger transcription factor that binds to GC-rich motifs of some promoters.29,30 Sp1 binding sites are located near the HRE regions on the promoter. More studies have shown that sp1 protein becomes overexpressed under hypoxic conditions.31 on the other side, hypoxic conditions have dual translation models known as cap-dependent and cap-independent (IRES) mechanisms. Notably, hypoxia has a strong restrictive effect on cap-dependent mRNA translation.32 However, cellular IRES has a significant role in adaptation to hypoxic stress but is not increased at translational level, possibly due to inhibition of protein synthesis in order to conserve energy. IRESs are natural translational enhancers and, hence, mediate internal initiation of translation when present between desired genes.

In clinical assays, bicistronic IRES-based expression vectors have fewer side effects than monocistronic based expression vectors. When we designed a vector for hypoxia-inducible expression, strong viral IRESs were used for efficient cap-independent gene expression. Fundamentally, the IRES-based expression vector is efficient for in vitro and in vivo gene expression under hypoxic conditions.33 Encephalomyocarditis virus (EMCV) is on-route into clinical studies and will hopefully be beneficial for patients. Our research, however, focused on in vitro studies. It is essential to study this cassette in vivo to evaluate all hypoxia-specific elements, such as enhancers (sp1, ARNT, and IRES) in a heterogenic population of myoblast and adult myocytes. However, we demonstrated that these elements were efficient for gene expression on hypoxic myoblasts in an in vitro model.

Conclusion

In conclusion, combination of the cardiac/muscle specific cis-regulatory elements, CASQ2, and myosin light chain-2 (MLC2v) have a significant specificity for myocytes. Both CASQ2 and MLC2v have a specific TFBS, which is efficient for cardiac-specific transgene expression. Sp1 binding sites are located near the HRE regions on the promoter. Therefore, Sp1 and HIF-1α have binding sites to a far distance of HREs derived from three promoters. Therefore, there is no longer need to overlap PCR process for one repeated sequence just in one promoter. This expression cassette well-designed for cardiac specific hypoxia inducible gene expression.

Acknowledgments

This work was a part of Ph.D. thesis and supported by the Research Council, Tabriz University of Medical Sciences. The authors thank the personnel of Immunology Research Center, Department of Pharmaceutical biotechnology for their kind guidance.

Ethical Issues

Not applicable.

Conflict of Interest

The authors declare “no” conflict of interest.

Abbreviations

HREs: hypoxia response elements, HIF-1α: hypoxia inducible factor-1 alpha, VEGF-A: vascular endothelial growth factor-A, PGK-1: phosphoglycerate kinase 1, MLC2v: myosin light chain, EPO: erythropoietin, ARNT: aryl hydrocarbon receptor nuclear translocator, eGFP: enhanced green fluorescent protein, CASQ2: calsequestrin 2, bHLH: basic helix-loop-helix , PAS: PER-ARNT-SIM, EMCV: encephalomyocarditis virus, UTR: untranslated region, IRES: internal ribosome entry site, MRFs: myogenic regulatory factors, MYOD1: myogenic differentiation 1, MYF5: myogenic factor 5, MYF6: myogenic factor 6, MHC-α: myosin heavy chain- alpha, TBX2: T box protein 2, NKX2-5: NK2 homeobox 5.

References

  • 1.Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci. 1995;92(12):5510–4. doi: 10.1073/pnas.92.12.5510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ. et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659–69. doi: 10.1182/blood-2004-07-2958. [DOI] [PubMed] [Google Scholar]
  • 3.Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH. et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 1997;51(2):553–5. doi: 10.1038/ki.1997.77. [DOI] [PubMed] [Google Scholar]
  • 4.Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW. et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature. 2002;417(6892):975–8. doi: 10.1038/nature00767. [DOI] [PubMed] [Google Scholar]
  • 5.Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol. 2014;76:39–56. doi: 10.1146/annurev-physiol-021113-170322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47–71. doi: 10.1146/annurev-pathol-012513-104720. [DOI] [PubMed] [Google Scholar]
  • 7.GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden Of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi: 10.1016/S0140-6736(14)61682-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Su H, Joho S, Huang Y, Barcena A, Arakawa-Hoyt J, Grossman W. et al. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl Acad Sci U S A. 2004;101(46):16280–5. doi: 10.1073/pnas.0407449101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Matkar PN, Leong-Poi H, Singh KK. Cardiac gene therapy: Are we there yet? Gene Ther. 2016;23(8-9):635–48. doi: 10.1038/gt.2016.43. [DOI] [PubMed] [Google Scholar]
  • 10.Warlich E, Kuehle J, Cantz T, Brugman MH, Maetzig T, Galla M. et al. Lentiviral vector design and imaging approaches to visualize the early stages of cellular reprogramming. Mol Ther. 2011;19(4):782–9. doi: 10.1038/mt.2010.314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308. doi: 10.1038/nprot.2013.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. 2011;29(8):731–4. doi: 10.1038/nbt.1927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lim WA. Designing customized cell signalling circuits. Nat Rev Mol Cell Biol. 2010;11(6):393–403. doi: 10.1038/nrm2904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Reyes-Juarez JL, Juarez-Rubi R, Rodriguez G, Zarain-Herzberg A. Transcriptional analysis of the human cardiac calsequestrin gene in cardiac and skeletal myocytes. J Biol Chem. 2007;282(49):35554–63. doi: 10.1074/jbc.M707788200. [DOI] [PubMed] [Google Scholar]
  • 15.Razi Soofiyani S, Baradaran B, Lotfipour F, Kazemi T, Mohammadnejad L. Gene therapy, early promises, subsequent problems, and recent breakthroughs. Adv Pharm Bull. 2013;3(2):249–55. doi: 10.5681/apb.2013.041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Li X, Sui X, Zhang Y, Sun Y, Zhao Y, Zhai Y. et al. An improved calcium chloride method preparation and transformation of competent cells. Afr J Biotechnol. 2010;9(50):8549–54. [Google Scholar]
  • 17.Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature. 1977;270(5639):725–7. doi: 10.1038/270725a0. [DOI] [PubMed] [Google Scholar]
  • 18.Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399–405. [PubMed] [Google Scholar]
  • 19. Chen CW, Wu SY, Hu GM. Single Differentiated Neurons from Pluripotent Embryonic Stem Cells: Motor Protein Modeling and Neurodegenerative Disease. In: Tseng FG, Santra TS, editor. Essentials of Single-Cell Analysis. 1st ed. Springer-Verlag Berlin Heidelberg; 2016. PP. 383-414.
  • 20.Flanagan M, Gimble JM, Yu G, Wu X, Xia X, Hu J. et al. Competitive electroporation formulation for cell therapy. Cancer Gene Ther. 2011;18(8):579–86. doi: 10.1038/cgt.2011.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mansoori B, Sandoghchian Shotorbani S, Baradaran B. RNA interference and its role in cancer therapy. Adv Pharm Bull. 2014;4(4):313–21. doi: 10.5681/apb.2014.046. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Rindt H, Knotts S, Robbins J. Segregation of cardiac and skeletal muscle-specific regulatory elements of the beta-myosin heavy chain gene. Proc Natl Acad Sci U S A. 1995;92(5):1540–4. doi: 10.1073/pnas.92.5.1540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Sheikh F, Lyon RC, Chen J. Functions of myosin light chain-2 (MYL2) in cardiac muscle and disease. Gene. 2015;569(1):14–20. doi: 10.1016/j.gene.2015.06.027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Habets PE, Moorman AF, Clout DE, van Roon MA, Lingbeek M, van Lohuizen M. et al. Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: Implications for cardiac chamber formation. Genes Dev. 2002;16(10):1234–46. doi: 10.1101/gad.222902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Rincon MY, Sarcar S, Danso-Abeam D, Keyaerts M, Matrai J, Samara-Kuko E. et al. Genome-wide computational analysis reveals cardiomyocyte-specific transcriptional Cis-regulatory motifs that enable efficient cardiac gene therapy. Mol Ther. 2015;23(1):43–52. doi: 10.1038/mt.2014.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lindebro MC, Poellinger L, Whitelaw ML. Protein-protein interaction via PAS domains: role of the PAS domain in positive and negative regulation of the bHLH/PAS dioxin receptor-Arnt transcription factor complex. EMBO J. 1995;14(14):3528–39. doi: 10.1002/j.1460-2075.1995.tb07359.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Ghaderi S, Alidadiani N, Dilaver N, Heidari HR, Parvizi R, Rahbarghazi R. et al. Role of glycogen synthase kinase following myocardial infarction and ischemia-reperfusion. Apoptosis. 2017;22(7):887–97. doi: 10.1007/s10495-017-1376-0. [DOI] [PubMed] [Google Scholar]
  • 28.Wang FS, Wang CJ, Chen YJ, Chang PR, Huang YT, Sun YC. et al. Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1alpha and VEGF-A expression in shock wave-stimulated osteoblasts. J Biol Chem. 2004;279(11):10331–7. doi: 10.1074/jbc.M308013200. [DOI] [PubMed] [Google Scholar]
  • 29.Lan S, Ostberg S, Punga T, Akusjarvi G. A suppressive effect of Sp1 recruitment to the first leader 5' splice site region on L4-22K-mediated activation of the adenovirus major late promoter. Virus Res. 2015;210:133–40. doi: 10.1016/j.virusres.2015.07.026. [DOI] [PubMed] [Google Scholar]
  • 30.Yang G, Pei Y, Teng H, Cao Q, Wang R. Specificity protein-1 as a critical regulator of human cystathionine gamma-lyase in smooth muscle cells. J Biol Chem. 2011;286(30):26450–60. doi: 10.1074/jbc.M111.266643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol. 2009;29(10):2483–8. doi: 10.1128/MCB.01828-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature. 2005;433(7025):477–80. doi: 10.1038/nature03205. [DOI] [PubMed] [Google Scholar]
  • 33.Fernandez-Chamorro J, Lozano G, Garcia-Martin JA, Ramajo J, Dotu I, Clote P. et al. Designing synthetic RNAs to determine the relevance of structural motifs in picornavirus IRES elements. Sci Rep. 2016;6:24243. doi: 10.1038/srep24243. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Advanced Pharmaceutical Bulletin are provided here courtesy of Tabriz University of Medical Sciences

RESOURCES